65,437 trials
Healthy
Primary: Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation — 66.2; 111…
Analgesia, Obstetrical · Coagulation Defect; Postpartum · Nonsteroidals (NSAIDs)Toxicity
Primary: Platelet Aggregometry — 65.4; 59.1 Percentage of light transmission
Impacted Mandibular Third Molar Extraction · Dental Anxiety
Primary: Change in Systolic Blood Pressure (SBP) — 115.04; 112.04; 113.58; 113.58 mm Hg — p=0.579
Family Relationship · Stress · Breastfeeding
Primary: Parent Stressor Scale: Neonatal Intensive Care Unit (PSS: NICU) — 2.86; 2.48; 3.19; 2.23 score on a scale — p==0.006
Hepatic Insufficiency · Hepatic Impairment
Primary: Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide — 540; 559 nM·hr
Intestinal Failure · CRBSI - Catheter Related Bloodstream Infection
Primary: Rate of Catheter Related Bloodstream Infections — 8.2; 3.0 infections per 1000 catheter days
SARS-CoV-2 Infection, COVID-19
Primary: Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age — 12.5; 0; 100.0; 16.7 Percentage of participants
Perioperative Optimization
Primary: 30 Day Hospital Free Days — 27; 27; 26; 27 Number of hospital free days
NASH - Nonalcoholic Steatohepatitis
Primary: Safety and Tolerability of Treatment — 12; 13; 13; 18 Participants
Healthy
Primary: Tolerability Measured by Tolerability Questionnaire — 2; 2 score on a scale
Type 1 Diabetes
Primary: CGM-measured Time in Range (TIR, 70-180 mg/dL) During the 18-hour Hotel Sessions. — 85.7; 86.5 percentage of time — p=0.047
Chin Augmentation · Chin Retrusion
Primary: Change From Baseline in the Blinded Evaluators' Live Assessment Using the Galderma Chin Retrusion Scale (GCRS) at Month 3 — -0.94; -1.02 score on a scale
Chronic Kidney Diseases · Health Behaviors · Patient Education
Primary: The Results of eGFR at Each Time Poins From Baseline to 6, 12, 18, 24, and 30 Months — 74.3; 78.7; 74.04; 79.20 ml/min/1.73 m2 — p=0.01
Alcohol; Use, Problem · Stress · Binge Eating
Primary: Alcohol Consumption (AUDIT-C Score) — 2.933; 2.574; 3.167; 2.619 AUDIT-C score — p=0.4226
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus — 11; 4 Participants